USPTO Examiner CHANG KYUNG SOOK - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18818363TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDSAugust 2024April 2025Allow710YesNo
18624804Personal Care FormulationsApril 2024April 2025Allow1210NoNo
18435678EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATIONFebruary 2024March 2025Allow1310YesNo
18397626PROCESS OF MAKING NANOEMULSIONDecember 2023January 2025Allow1210NoNo
183865602-BENZO-[3,4-B] QUINOLINO-{B,G]INDENO [1',2':3,4] FLUORENO-[1,2-D] OXONINE-5,11,16,21-TETRAONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow401NoNo
183865793-(4-BROMOPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023August 2024Allow921NoNo
18493990COSMETIC COMPOSITIONS, KITS THEREOF, AND METHODS FOR MAKING AND USING THE SAMEOctober 2023June 2024Allow800YesNo
18365724TRANSDERMAL DELIVERY SYSTEM INCLUDING AN INTERFACE MEDIATORAugust 2023June 2025Allow2211YesNo
18357927INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICEJuly 2023January 2025Abandon1810NoNo
18345029DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATIONJune 2023July 2024Abandon1310NoNo
18336431Silk-Based Moisturizer Compositions and Methods ThereofJune 2023June 2025Allow2420NoNo
18334667PUTRESCINE TOPICAL BARRIER FORMULATIONJune 2023July 2024Abandon1310NoNo
18327267TOPICAL COMPOSITION COMPRISED OF COD LIVER OIL FOR TREATING WOUNDS AND SKIN DISORDERSJune 2023September 2024Allow1630YesNo
18327278TOPICAL COMPOSITION COMPRISED OF COD LIVER OIL FOR TREATING WOUNDS AND SKIN DISORDERSJune 2023September 2024Allow1530YesNo
18124128COMPOUND AND METHOD FOR TREATING DISEASES AND DISORDERSMarch 2023May 2025Abandon2630NoNo
18123268Fast Release Benzoic Acid In FeedMarch 2023July 2024Abandon1620NoNo
18121576STEROIDAL COMPOSITIONS AND METHOD OF MAKING AND USEMarch 2023July 2024Allow1720YesNo
18177720POLYGLUTAMIC ACID COMPOSITIONS AND METHODS OF USINGMarch 2023April 2025Allow2550YesNo
18115008TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTSFebruary 2023July 2024Abandon1710NoNo
18112635SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTSFebruary 2023February 2024Allow1220YesNo
18171070TASTE-MASKING ORAL FORMULATIONS OF FASUDILFebruary 2023July 2024Allow1740YesNo
18106684NATURAL POLYMER-BASED TISSUE ADHESIVE WITH HEALING-PROMOTING PROPERTIESFebruary 2023June 2024Allow1620NoNo
18149804FOOD GRADE WHITENING AGENTS AND USES THEREOFJanuary 2023May 2024Abandon1710NoNo
18056981TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDSNovember 2022August 2024Abandon2111NoNo
18055494EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATIONNovember 2022November 2023Allow1220NoNo
17923076AN ANTIMICROBIAL COMPOSITION FOR TACKLING MALODOURNovember 2022May 2025Allow3110NoNo
17970160KIT AND NEW METHOD OF TREATMENT FOR SKIN BASAL CELL AND SQUAMOUS CELL CARCINOMAOctober 2022July 2023Allow811NoNo
17967470COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONSOctober 2022July 2023Allow910NoNo
17939396POWDERED FORMULATIONS OF CROMOLYN SODIUM AND IBUPROFENSeptember 2022January 2024Abandon1610NoNo
17902646COSMETIC FORMULATIONSeptember 2022March 2024Abandon1930YesNo
17876700DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATIONJuly 2022August 2023Abandon1210NoNo
17877005Water-soluble Unidirectional Moisture Transport Traditional Chinese Medicine Facial Mask and Preparation thereofJuly 2022April 2024Allow2121YesNo
17871111Personal Care Compositions Incorporating Natural Benefit Agents and Methods for the SameJuly 2022May 2025Abandon3440NoNo
17758315ORAL SOLID CANNABINOID OIL COMPOSITION FOR TREATING GASTROINTESTINAL DISORDERSJuly 2022August 2024Allow2610NoNo
17848981COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASE INCLUDING PUER TEA EXTRACTJune 2022June 2025Allow3640YesYes
17831333TOPICAL COMPOSITION FOR HOMEOSTATIC DELIVERY OF NITRIC OXIDE AND USES THEREOFJune 2022June 2024Allow2420YesNo
17751883COSMETIC PRODUCT COMPRISING A COSMETIC COMPOSITION CONTAINED IN AN APPLICATORMay 2022June 2024Abandon2520NoNo
17746713COMPOSITION OF TANNIC ACID AND VITAMIN D AND METHODS OF USEMay 2022October 2023Abandon1710NoNo
17746555METHOD FOR WHITENING SKIN USING COMPOSITION FOR SKIN WHITENINGMay 2022February 2025Allow3340YesNo
17744685PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS THEREOFMay 2022November 2023Allow1820NoNo
17743895Personal Care FormulationsMay 2022December 2023Allow1920NoNo
17743537WET WIPES WITH A CELLULOSIC SUBSTRATE AND GENTLE LOTIONMay 2022December 2023Allow1920NoNo
17743529WET WIPES WITH A CELLULOSIC SUBSTRATE AND GENTLE LOTIONMay 2022January 2024Allow2020NoNo
17739246Hydrogel-Fabric Composite For Cosmetic ApplicationsMay 2022March 2024Abandon2210NoNo
17755408OIL-IN-WATER TYPE COMPOSITIONApril 2022June 2025Allow3820NoNo
17732162COMPOSITION AND METHOD FOR ODOR CONTROLApril 2022August 2023Allow1610NoNo
17730305STEROIDAL COMPOSITIONS AND METHOD OF MAKING AND USEApril 2022February 2023Allow1020NoNo
17728522ANTI-AGING AND SKIN TONE LIGHTENING COMPOSITIONS AND METHODS FOR SAMEApril 2022March 2025Abandon3440NoNo
17717868Personal Care CompositionApril 2022June 2023Allow1410NoNo
17766487ORAL CARE COMPOSITION COMPRISING CUTTLEFISH BONE POWDERApril 2022May 2025Abandon3810NoNo
17763236TREATMENT OF SKIN DISORDERS WITH TOPICAL COMBINATION COMPOSITIONS COMPRISING TAPINAROF AND AN ADDITIONAL AHR ACTIVATORMarch 2022May 2025Abandon3801NoNo
17761792COMPOSITIONS AND METHODS FOR RESTORING OR INCREASING TISSUE PERFUSIONMarch 2022March 2025Allow3610YesNo
17638713COMPOSITION, PROCESS AND KIT FOR SEMI-PERMANENT STRAIGHTENING AND CURLING OF KERATIN FIBERSFebruary 2022March 2025Abandon3610NoNo
17613448METHOD FOR STABILIZING HUMIDITY-SENSITIVE PHARMACEUTICAL SUBSTANCE AND STABILIZED PREPARATION THEREOFFebruary 2022February 2023Allow1530YesNo
17674728PRODUCING ATP AND IMPROVING MITOCHONDRIAL FUNCTION IN A MAMMAL USING A POLY-OXYGENATED METAL HYDROXIDEFebruary 2022April 2024Abandon2610NoNo
17666577COMPOSITION FOR STIMULATING MUSCLE GROWTH, REPAIR, AND MAINTENANCEFebruary 2022April 2023Allow1410NoNo
17666181COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONSFebruary 2022August 2022Allow610YesNo
17632959HIGH PERFORMANCE ANTIMICROBIAL COMPOSITIONFebruary 2022March 2025Abandon3810NoNo
17586618DEFINED DOSE CANNABIS PODJanuary 2022May 2025Abandon4021NoNo
17576202USE OF NUTRITIONAL COMPOSITIONS HAVING A LOW PROTEIN AMOUNTJanuary 2022April 2024Allow2720YesNo
17574511INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICEJanuary 2022April 2023Allow1510YesNo
17621930SKINCARE COMPOSITIONSDecember 2021December 2024Allow3620YesNo
17559143NANOPARTICLES AND METHODS FOR PREPARATION THEREOFDecember 2021July 2024Abandon3120NoNo
17548232PARENTERAL FORMULATIONSDecember 2021April 2024Allow2820YesNo
17534500Bijels And Methods Of Making The SameNovember 2021March 2025Allow4030YesNo
17530002METHOD FOR TREATING CANCER WITH A NANOFORMULATIONNovember 2021April 2023Allow1710NoNo
17528689Enteric Coated Multiparticulate Compositions With A Proteinaceous SubcoatNovember 2021July 2023Allow2010NoNo
17510162HYDROGEL PATCH INCLUDING ADDITIVE SOLUTION ADJUSTABLE FOR ITS SYNERESIS PATTERN AND METHOD OF MANUFACTURING THE COMPOSITIONOctober 2021September 2024Allow3501YesNo
17602571GEL CLEANSING AGENTOctober 2021July 2024Allow3410NoNo
17600852HAIR DYEOctober 2021April 2024Allow3100NoNo
17600582DEODORISING COMPOSITIONSeptember 2021February 2025Abandon4010NoNo
17449211DILUTABLE FORMULATIONS OF CANNABINOIDS AND PROCESSES FOR THEIR PREPARATIONSeptember 2021July 2023Allow2110YesNo
17598378COSMETIC COMPOSITIONSeptember 2021March 2025Allow4120YesNo
17478395PEDIATRIC DOSAGE FORMS, METHODS OF MAKING AND USINGSeptember 2021June 2024Allow3320YesYes
17472823CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURESeptember 2021June 2024Abandon3330NoNo
17438881COSMETIC PRODUCT CONTAINING A MIXTURE OF SILICONESSeptember 2021October 2024Abandon3710NoNo
17438362Novel Application for Inhibitors of cAMP Efflux in Body CareSeptember 2021January 2024Allow2810YesNo
17593127POTASSIUM-BINDING AGENTS FOR USE IN HEMODIALYSIS PATIENTSSeptember 2021April 2025Abandon4320NoNo
17467272ALCOHOL COMPOSITIONSeptember 2021April 2025Allow4330YesNo
17310990Personal Care CompositionsSeptember 2021August 2024Allow3630YesNo
17436250INDUCING CASPASE ACTIVITYSeptember 2021December 2024Allow3920NoNo
17434865COMPOSITION IN MICRO-ENCAPSULATED FORM, BASED ON N-BUTYRICACID OR DERIVATIVES THEREOF, FOR TREATING CROHNS DISEASE OR ULCERATIVE RECTAL COLITISAugust 2021November 2023Abandon2610NoNo
17402131MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORSAugust 2021December 2023Abandon2821NoNo
17429683POULTICEAugust 2021December 2023Allow2820NoNo
17396766ANTIBACTERIAL, DEODORIZATION, EASING OF ACNE AND ATOPY OR SKIN CALMING-FUNCTIONAL COMPOSITION FOR Y-ZONE CLEANLINESS CONTAINING QUERCUS ACUTISSIMA SAP AND ZINC RICINOLEATEAugust 2021July 2023Abandon2410NoNo
17375588TOPICAL COMPOSITION USING A TWO-PART FORM FACTORJuly 2021November 2023Abandon2821YesNo
17421978PHARMACEUTICAL DELIVERY COMPOSITIONS AND USES THEREOFJuly 2021April 2025Allow4541YesNo
17368724METHOD FOR PREVENTING OR TREATING INFECTION OF RESPIRATORY VIRUS UTILIZING GOLD NANOPARTICLESJuly 2021May 2022Abandon1120NoNo
17359991WATER-SOLUBLE FILM AND PACKAGEJune 2021October 2024Allow3910YesNo
17358616Cardiovascular ProsthesesJune 2021October 2024Abandon4010NoNo
17416925HAIR CARE COMPOSITIONJune 2021August 2024Allow3810YesNo
17416204COSMETIC COMPOSITION FOR KERATIN FIBRES COMPRISING A FATTY ACID ESTERJune 2021October 2024Abandon4010NoNo
17416167COSMETIC COMPOSITION FOR KERATIN FIBERS COMPRISING A FATTY ACID ESTERJune 2021October 2024Abandon4010NoNo
17415206PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN AROMATIC ORGANIC ANIONJune 2021May 2025Allow4721NoNo
17350088Hair conditioning composition with antimicrobial systemJune 2021February 2024Allow3230NoNo
17350478PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTSJune 2021April 2022Allow1020YesNo
17415602PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN ALIPHATIC DICARBOXYLIC ACID ANIONJune 2021April 2025Allow4621YesNo
17414781DYE COMPOSITION COMPRISING AT LEAST ONE POLYSACCHARIDE-TYPE POLYMER AND PROCESS FOR DYEING KERATIN FIBERS USING SAMEJune 2021July 2025Abandon4830NoNo
17414470HAIR CONDITIONING COMPOSITION FOR IMPROVED DEPOSITIONJune 2021May 2025Allow4730YesNo
17414181DEPOSITION SYSTEM FOR HAIRJune 2021December 2024Allow4220NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANG, KYUNG SOOK.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
19
Examiner Affirmed
15
(78.9%)
Examiner Reversed
4
(21.1%)
Reversal Percentile
33.2%
Lower than average

What This Means

With a 21.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
74
Allowed After Appeal Filing
14
(18.9%)
Not Allowed After Appeal Filing
60
(81.1%)
Filing Benefit Percentile
20.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CHANG, KYUNG SOOK - Prosecution Strategy Guide

Executive Summary

Examiner CHANG, KYUNG SOOK works in Art Unit 1613 and has examined 770 patent applications in our dataset. With an allowance rate of 61.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 26 months.

Allowance Patterns

Examiner CHANG, KYUNG SOOK's allowance rate of 61.3% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHANG, KYUNG SOOK receive 2.38 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHANG, KYUNG SOOK is 26 months. This places the examiner in the 59% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +40.1% benefit to allowance rate for applications examined by CHANG, KYUNG SOOK. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.3% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 34.6% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 107.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 77% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 64.2% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 64.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 54.2% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 47% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.